Stone M D, Hosking D J, Garcia-Himmelstine C, White D A, Rosenblum D, Worth H G
Metabolic Unit, University Hospital, Nottingham, UK.
Bone. 1993 Sep-Oct;14(5):727-35. doi: 10.1016/8756-3282(93)90204-n.
Resistance to the renal actions of parathyroid hormone (PTH) in pseudohypoparathyroidism (PsH) may be improved after treatment with vitamin D or its metabolites, but reports conflict. We have examined the renal response to infusion of 35 micrograms of 1-38 PTH in patients with PsH type I (n = 8) and PsH type II (n = 1) during treatment and related this to prevailing endogenous serum PTH and calcium levels. Nine patients with postsurgical or idiopathic hypoparathyroidism (HP) served as controls. The urinary cAMP increase (delta cAMP) was lower (p < 0.001) in the PsH type I (175 +/- 6.4 nmol/l glomerular filtrate) than in the HP group (3251 +/- 515 nmol/l glomerular filtrate). delta cAMP in the PsH type I subjects was dependent on endogenous PTH concentrations (r = -0.76; p = 0.046) and serum calcium (r = 0.74; p = 0.037). Phosphaturic responses (expressed as % decrease in TmPO4/glomerular filtration rate) were lower (p = 0.013) in the PsH type I (28.8 +/- 3.75) compared with those of the HP patients (43 +/- 3.48). The phosphaturic responses in the PsH type I patients were strongly dependent on endogenous PTH (r = 0.94; p < 0.001) and serum calcium levels (r = 0.94; p < 0.001) so that the responses of subjects with normal or low PTH levels were no different (p = 0.16) from the HP group. Renal handling of calcium and sodium in response to exogenous PTH was identical in patients with PsH (types I and II) and HP. Renal tubular reabsorption during a calcium infusion was normal in all patients with PsH. These results emphasise the importance of the modulatory effects due to associated biochemical abnormalities in PsH on the responses to exogenous PTH. They also confirm that renal handling of calcium and sodium is probably normal in treated PsH.
假性甲状旁腺功能减退症(PsH)患者对甲状旁腺激素(PTH)肾脏作用的抵抗,在接受维生素D或其代谢产物治疗后可能会有所改善,但相关报道存在矛盾。我们研究了I型PsH患者(n = 8)和II型PsH患者(n = 1)在治疗期间静脉输注35微克1-38 PTH后的肾脏反应,并将其与当时的内源性血清PTH和钙水平相关联。9例术后或特发性甲状旁腺功能减退症(HP)患者作为对照。I型PsH患者尿中环磷酸腺苷(cAMP)增加量(δcAMP)[每升肾小球滤过液中增加175±6.4纳摩尔]低于HP组[每升肾小球滤过液中增加3251±515纳摩尔](p < 0.001)。I型PsH患者的δcAMP取决于内源性PTH浓度(r = -0.76;p = 0.046)和血清钙(r = 0.74;p = 0.037)。I型PsH患者的磷尿反应[以TmPO4/肾小球滤过率的降低百分比表示](28.8±3.75)低于HP患者(43±3.48)(p = 0.013)。I型PsH患者的磷尿反应强烈依赖于内源性PTH(r = 0.94;p < 0.001)和血清钙水平(r = 0.94;p < 0.001),因此PTH水平正常或较低的患者的反应与HP组无差异(p = 0.16)。PsH(I型和II型)患者和HP患者对外源性PTH的钙和钠肾脏处理相同。所有PsH患者在钙输注期间的肾小管重吸收均正常。这些结果强调了PsH中相关生化异常对外源性PTH反应的调节作用的重要性。它们还证实,在接受治疗的PsH患者中,钙和钠的肾脏处理可能正常。